Pyxis Oncology (PYXS) Interest & Investment Income (2020 - 2026)
Pyxis Oncology (PYXS) posted quarterly Interest & Investment Income of -$50000.0 for Q4 2025, down 107.25% year-over-year from $690000.0 in Q4 2024, and down 109.4% quarter-over-quarter from $532000.0 in Q3 2025.
Pyxis Oncology (PYXS) Interest & Investment Income (2020 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported Interest & Investment Income for 6 consecutive years, with -$50000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Interest & Investment Income fell 107.25% year-over-year to -$50000.0; the TTM figure through Dec 2025 stood at $2.6 million (down 56.91% YoY), while the FY2025 annual figure was $3.0 million, down 51.55% from the prior year.
- Interest & Investment Income eased to -$50000.0 in Q4 2025 per PYXS's latest filing, from $532000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $2.0 million in Q2 2024 and bottomed at -$1.5 million in Q4 2023.
- Historically, Interest & Investment Income has averaged $668800.0 across 5 years, with a median of $648500.0 in 2023.
- Annual changes were most pronounced in 2022 — Interest & Investment Income soared 26642.86% — and 2023, when it sank 180.4%.
- Pyxis Oncology's Interest & Investment Income stood at $7000.0 in 2021, then jumped by 26642.86% to $1.9 million in 2022, then tumbled by 180.4% to -$1.5 million in 2023, then soared by 145.85% to $690000.0 in 2024, then tumbled by 107.25% to -$50000.0 in 2025.
- Business Quant data shows PYXS's Interest & Investment Income at -$50000.0 in Q4 2025, $532000.0 in Q3 2025, and $995000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - | 300,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 300,000.00 |
| Dec 31, 2025 | -50,000.00 |
| Sep 30, 2025 | 532,000.00 |
| Jun 30, 2025 | 995,000.00 |
| Mar 31, 2025 | 1.16 Mn |
| Dec 31, 2024 | 690,000.00 |
| Sep 30, 2024 | 1.80 Mn |
| Jun 30, 2024 | 2.02 Mn |
| Mar 31, 2024 | 1.60 Mn |
| Dec 31, 2023 | -1.51 Mn |
| Sep 30, 2023 | 1.48 Mn |
| Jun 30, 2023 | 1.26 Mn |
| Mar 31, 2023 | 607,000.00 |
| Dec 31, 2022 | 1.87 Mn |
| Sep 30, 2022 | 719,000.00 |
| Jun 30, 2022 | 164,000.00 |
| Mar 31, 2022 | 9,000.00 |
| Dec 31, 2021 | 7,000.00 |
| Sep 30, 2021 | 6,000.00 |
| Jun 30, 2021 | 6,000.00 |